Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

Should the FDA have rejected Contrave?

Daniel J. Carlat, MD
Meds
April 13, 2011
Share
Tweet
Share

Recently, the FDA has rejected another anti-obesity drug, Contrave, because of concerns that it might cause heart attacks in patients who take it for years.

FDA’s excessive caution was motivated by its experience having been burned by the Fen-Phen fiasco. This was a weight loss drug widely prescribed in the 90s that was pulled from the market after studies showed it caused fatal lung and heart valve problems.

This new drug, however, is a combination of two medications that have already been widely prescribed and are fairly safe: Wellbutrin and naltrexone. Psychiatrists are familiar with both of them. We prescribe Wellbutrin for depression and smoking cessation, (and off-label for weight loss, for which it has shown efficacy as a stand alone), and we prescribe naltrexone for alcoholism.

As you can see from information published on Clinicaltrials.gov, Contrave is simply a combination of Wellbutrin 400 mg with Naltrexone at a couple of different doses, 48 mg and 16 mg. Clinical trials showed that Contrave helped 50% of obese patients lose 5% of their body weight, while only 10% of patients on placebo lost that much weight. The FDA’s advisory panel voted to recommend approval, but the FDA demurred, saying that the company, Orexigen, will have to conduct a huge placebo-controlled long term study to make sure the drug doesn’t cause heart attacks (one of Wellbutrin’s well-known side effects is a slight increase in pulse and blood pressure, although there were no heart attacks in the Contrave clincial trials).

In my opinion, the FDA made the wrong decision. Obesity is a public health catastrophe, and Contrave’s approval would have been predicated on conducting post-marketing safety studies anyway. The good news is that patients can ask doctors to prescribe them the constituents of Contrave, both of which are available in generic form–burpropion and naltrexone. Presumably, this generic combination will be much cheaper than Contrave’s pricing anyway.

Daniel Carlat is a psychiatrist and author of Unhinged: The trouble with psychiatry- a doctor’s revelations about a profession in crisis.

Submit a guest post and be heard on social media’s leading physician voice.

Prev

USA Today op-ed on end of life care and advance directives

April 13, 2011 Kevin 1
…
Next

Policies prohibiting collaboration between physicians and industry

April 13, 2011 Kevin 3
…

Tagged as: Medications

Post navigation

< Previous Post
USA Today op-ed on end of life care and advance directives
Next Post >
Policies prohibiting collaboration between physicians and industry

ADVERTISEMENT

More by Daniel J. Carlat, MD

  • a desk with keyboard and ipad with the kevinmd logo

    Elimination of industry support for CME

    Daniel J. Carlat, MD
  • a desk with keyboard and ipad with the kevinmd logo

    The decision point psychiatrists faced with psychotherapy

    Daniel J. Carlat, MD
  • a desk with keyboard and ipad with the kevinmd logo

    ProPublica’s Dollars for Docs: Strengths and weaknesses

    Daniel J. Carlat, MD

More in Meds

  • Oral Wegovy: the miracle and the mess of the new GLP-1 pill

    Shiv K. Goel, MD
  • U.S. opioid policy history: How politics replaced science in pain care

    Richard A. Lawhern, PhD & Stephen E. Nadeau, MD
  • How CAR-NK cancer therapy could be safer than CAR-T

    Cliff Dominy, PhD
  • Psychedelic-assisted therapy: science, safety, and regulation

    Muhamad Aly Rifai, MD
  • The anticoagulant evidence controversy: a whistleblower’s perspective

    David K. Cundiff, MD
  • Is tramadol really ineffective and risky?

    John A. Bumpus, PhD
  • Most Popular

  • Past Week

    • My wife’s story: How DEA and CDC guidelines destroyed our golden years

      Monty Goddard & Richard A. Lawhern, PhD | Conditions
    • The hidden costs of the physician non-clinical career transition

      Carlos N. Hernandez-Torres, MD | Physician
    • The gastroenterologist shortage: Why supply is falling behind demand

      Brian Hudes, MD | Physician
    • Health care as a human right vs. commodity: Resolving the paradox

      Timothy Lesaca, MD | Physician
    • Why private equity is betting on employer DPC over retail

      Dana Y. Lujan, MBA | Policy
    • Why voicemail in outpatient care is failing patients and staff

      Dan Ouellet | Tech
  • Past 6 Months

    • Physician on-call compensation: the unpaid labor driving burnout

      Corinne Sundar Rao, MD | Physician
    • How environmental justice and health disparities connect to climate change

      Kaitlynn Esemaya, Alexis Thompson, Annique McLune, and Anamaria Ancheta | Policy
    • Will AI replace primary care physicians?

      P. Dileep Kumar, MD, MBA | Tech
    • A physician father on the Dobbs decision and reproductive rights

      Travis Walker, MD, MPH | Physician
    • What is the minority tax in medicine?

      Tharini Nagarkar and Maranda C. Ward, EdD, MPH | Education
    • Why the U.S. health care system is failing patients and physicians

      John C. Hagan III, MD | Policy
  • Recent Posts

    • When diagnosis becomes closure: the harm of stopping too soon

      Ann Lebeck, MD | Physician
    • Celiac disease psychiatric symptoms: When anxiety is autoimmune

      Carrie Friedman, NP | Conditions
    • Prostate cancer screening limitations: Why PSA isn’t enough

      Francisco M. Torres, MD | Conditions
    • From flight surgeon to investor: a doctor’s guide to financial freedom

      David B. Mandell, JD, MBA | Physician
    • Why perimenopause feels like losing yourself

      Claudine Holt, MD | Conditions
    • The surgical safety checklist: Why silence is the real enemy

      Brooke Buckley, MD, MBA | Physician

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

View 6 Comments >

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

ADVERTISEMENT

ADVERTISEMENT

  • Most Popular

  • Past Week

    • My wife’s story: How DEA and CDC guidelines destroyed our golden years

      Monty Goddard & Richard A. Lawhern, PhD | Conditions
    • The hidden costs of the physician non-clinical career transition

      Carlos N. Hernandez-Torres, MD | Physician
    • The gastroenterologist shortage: Why supply is falling behind demand

      Brian Hudes, MD | Physician
    • Health care as a human right vs. commodity: Resolving the paradox

      Timothy Lesaca, MD | Physician
    • Why private equity is betting on employer DPC over retail

      Dana Y. Lujan, MBA | Policy
    • Why voicemail in outpatient care is failing patients and staff

      Dan Ouellet | Tech
  • Past 6 Months

    • Physician on-call compensation: the unpaid labor driving burnout

      Corinne Sundar Rao, MD | Physician
    • How environmental justice and health disparities connect to climate change

      Kaitlynn Esemaya, Alexis Thompson, Annique McLune, and Anamaria Ancheta | Policy
    • Will AI replace primary care physicians?

      P. Dileep Kumar, MD, MBA | Tech
    • A physician father on the Dobbs decision and reproductive rights

      Travis Walker, MD, MPH | Physician
    • What is the minority tax in medicine?

      Tharini Nagarkar and Maranda C. Ward, EdD, MPH | Education
    • Why the U.S. health care system is failing patients and physicians

      John C. Hagan III, MD | Policy
  • Recent Posts

    • When diagnosis becomes closure: the harm of stopping too soon

      Ann Lebeck, MD | Physician
    • Celiac disease psychiatric symptoms: When anxiety is autoimmune

      Carrie Friedman, NP | Conditions
    • Prostate cancer screening limitations: Why PSA isn’t enough

      Francisco M. Torres, MD | Conditions
    • From flight surgeon to investor: a doctor’s guide to financial freedom

      David B. Mandell, JD, MBA | Physician
    • Why perimenopause feels like losing yourself

      Claudine Holt, MD | Conditions
    • The surgical safety checklist: Why silence is the real enemy

      Brooke Buckley, MD, MBA | Physician

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

Should the FDA have rejected Contrave?
6 comments

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...